Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Esomeprazole Sodium

FDA-approved product (injectable, intravenous), marketed as Esomeprazole Magnesium, Nexium, Nexium 24hr and 3 more.

Registered studies
46
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Esomeprazole Sodium
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Ankylosing spondylitis
  • Duodenal ulcer
  • Esophagitis
  • Gastric ulcer
  • Gastroesophageal reflux disease
  • Osteoarthritis
  • Rheumatoid arthritis
  • Zollinger-Ellison Syndrome

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Proton pump inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA34.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli43.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae12.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis30.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

46registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Esomeprazole Sodium in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Esomeprazole Sodium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • The Clinical Trail to Evaluate the Efficacy and Safety of Anaprazole Sodium Enteric-coated Tablets Combined With Bismuth-containing Quadruple Therapy in Eradicating Helicobacter Pylori

    NCT07606833 · start 2026-06-10

    Registered record
    Registry ID
    NCT07606833
    Conditions
    HELICOBACTER PYLORI INFECTIONS
    Interventions
    Anaprazole Sodium enteric-coated tablet; Esomeprazole magnesium enteric-coated tablets
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2026-06-10
    Completion
    2027-03-18
    Enrolment
    556

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHELICOBACTER PYLORI INFECTIONS
    InterventionAnaprazole Sodium enteric-coated tablet; Esomeprazole magnesium enteric-coated tablets
    PhasePhase 3
    Registry statusNot yet recruiting

  • Esomeprazole Plus Sucralfate for Post-ESD Ulcer Healing

    NCT07312370 · start 2026-04-20

    Registered record
    Registry ID
    NCT07312370
    Conditions
    Early Gastric Cancer; Gastric Dysplasia; Gastric Neoplasms; Peptic Ulcer With Haemorrhage; Gastric Ulcer
    Interventions
    Esomeprazole (Intravenous); Esomeprazole (Oral); Sucralfate Suspension; Gastric Endoscopic Submucosal Dissection (ESD)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2026-04-20
    Completion
    2026-12-30
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEarly Gastric Cancer; Gastric Dysplasia; Gastric Neoplasms; Peptic Ulcer With Haemorrhage +1 more
    InterventionEsomeprazole (Intravenous); Esomeprazole (Oral); Sucralfate Suspension; Gastric Endoscopic Submucosal Dissection (ESD)
    PhasePhase 4
    Registry statusNot yet recruiting

  • Drug Interaction Study on Linaprazan Glurate Capsules

    NCT07294846 · start 2025-09-08

    Registered record
    Registry ID
    NCT07294846
    Conditions
    Healthy Volunteers; Patients
    Interventions
    Linaprazan Glurate Capsules; Bismuth Potassium Citrate Capsules; Amoxicillin Capsules; Clarithromycin tablets; Esomeprazole Magnesium Enteric-coated Tablets
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2025-09-08
    Completion
    2025-12-15
    Enrolment
    56

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers; Patients
    InterventionLinaprazan Glurate Capsules; Bismuth Potassium Citrate Capsules; Amoxicillin Capsules; Clarithromycin tablets +1 more
    PhasePhase 1
    Registry statusCompleted

  • A Phase III Clinical Trial for Efficacy and Safety Evaluation of JP-1366 Tablets on Reflux Esophagitis

    NCT06850480 · start 2024-12-05

    Registered record
    Registry ID
    NCT06850480
    Conditions
    Reflux Esophagitis (RE)
    Interventions
    JP-1366 simulation tablets; Esomeprazole Magnesium (Nexium) simulation tablets
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2024-12-05
    Completion
    2025-04-30
    Enrolment
    356

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionReflux Esophagitis (RE)
    InterventionJP-1366 simulation tablets; Esomeprazole Magnesium (Nexium) simulation tablets
    PhasePhase 3
    Registry statusRecruiting

  • Esomeprazole Magnesium Dihydrate 40 mg Tablets Relative to Nexium 40 mg Tablets Under Fed Condition

    NCT06233149 · start 2024-10-01

    Registered record
    Registry ID
    NCT06233149
    Conditions
    Healthy Subjects
    Interventions
    Esomeprazole magnesium dihydrate-Test product; Esomeprazole magnesium dihydrate-Reference product
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Unknown
    Start
    2024-10-01
    Completion
    2024-12-03
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Subjects
    InterventionEsomeprazole magnesium dihydrate-Test product; Esomeprazole magnesium dihydrate-Reference product
    PhasePhase 1
    Registry statusUnknown

  • Esomeprazole Magnesium Dihydrate 40 mg Tablets Relative to Nexium 40 mg Tablets Under Fasting Condition

    NCT06233097 · start 2024-08-29

    Registered record
    Registry ID
    NCT06233097
    Conditions
    Healthy Subjects
    Interventions
    Esomeprazole magnesium dihydrate-Test product; Esomeprazole magnesium dihydrate-Reference product
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Unknown
    Start
    2024-08-29
    Completion
    2024-10-12
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Subjects
    InterventionEsomeprazole magnesium dihydrate-Test product; Esomeprazole magnesium dihydrate-Reference product
    PhasePhase 1
    Registry statusUnknown

  • Efficacy and Safety of Tegoprazan Versus Esomeprazole-containing Bismuth Quadruple Therapy for Eradication of Helicobacter Pylori

    NCT05577468 · start 2022-10-30

    Registered record
    Registry ID
    NCT05577468
    Conditions
    Helicobacter Pylori Infection
    Interventions
    Tegoprazan
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2022-10-30
    Completion
    2023-09-30
    Enrolment
    561

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection
    InterventionTegoprazan
    PhasePhase 3
    Registry statusCompleted

  • Furazolidone Quadruple Regimen Eradicate H. Pylori Infection

    NCT06823791 · start 2022-08-01

    Registered record
    Registry ID
    NCT06823791
    Conditions
    Helicobacter Pylori Infection; Eradication
    Interventions
    Furazolidone; Clarithromycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2022-08-01
    Completion
    2024-07-30
    Enrolment
    493

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection; Eradication
    InterventionFurazolidone; Clarithromycin
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • The Effect of PPI in Preventing Gastroesophageal Reflux Disease of Seafarers

    NCT04696783 · start 2021-07

    Registered record
    Registry ID
    NCT04696783
    Conditions
    Gastroesophageal Reflux Disease
    Interventions
    Esomeprazole Magnesium Enteric-coated Tablets; Lifestyle adjustment
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2021-07
    Completion
    2021-11
    Enrolment
    92

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastroesophageal Reflux Disease
    InterventionEsomeprazole Magnesium Enteric-coated Tablets; Lifestyle adjustment
    PhasePhase 3
    Registry statusUnknown

  • Whether Proton Pump Inhibitors, Administered Prior to or After Surgery, Can Reduce the Incidence and/or Severity of Difficulty Swallowing Foods and/or Liquids,Following Anterior Cervical Surgery

    NCT03488147 · start 2020-07

    Registered record
    Registry ID
    NCT03488147
    Conditions
    Dysphagia; GERD; Degenerative Joint Disease
    Interventions
    Esomeprazole; Placebo Oral Tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2020-07
    Completion
    2020-07-02
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDysphagia; GERD; Degenerative Joint Disease
    InterventionEsomeprazole; Placebo Oral Tablet
    PhasePhase 2
    Registry statusWithdrawn

  • Clinical Trial to Assess the PK/PD of YYD601 20mg After Oral Administration if Healthy Adult Subjects (Phase1)

    NCT03985319 · start 2019-07-08

    Registered record
    Registry ID
    NCT03985319
    Conditions
    GERD
    Interventions
    YYD601 20mg; Nexium tab 20mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2019-07-08
    Completion
    2020-03-20
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGERD
    InterventionYYD601 20mg; Nexium tab 20mg
    PhasePhase 1
    Registry statusCompleted

  • Effect of Probiotics on Helicobacter Pylori Eradication

    NCT04034641 · start 2019-06-17

    Registered record
    Registry ID
    NCT04034641
    Conditions
    Helicobacter Pylori Eradication
    Interventions
    Bifidobacterium tetrad live bacteria tablet plus Helicobacter pylori quadruple eradication therapy; Bifidobacterium tetrad live bacteria tablet placebo plus Helicobacter pylori quadruple eradication therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2019-06-17
    Completion
    2021-12-31
    Enrolment
    238

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Eradication
    InterventionBifidobacterium tetrad live bacteria tablet plus Helicobacter pylori quadruple eradication therapy; Bifidobacterium tetrad live bacteria tablet placebo plus Helicobacter pylori quadruple eradication therapy
    PhasePhase 4
    Registry statusUnknown

  • Clinical Trial to Assess the Efficacy and Safety of YYD601 in NERD Patients

    NCT03967886 · start 2019-04-10

    Registered record
    Registry ID
    NCT03967886
    Conditions
    Non-erosive Reflux Disease
    Interventions
    YYD601 20mg; Nexium 20mg; Placebos
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2019-04-10
    Completion
    2020-05-27
    Enrolment
    170

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-erosive Reflux Disease
    InterventionYYD601 20mg; Nexium 20mg; Placebos
    PhasePhase 3
    Registry statusCompleted

  • Clinical Trial to Assess the Efficacy and Safety of YYD601 in the Treatment of Esophageal Reflux Disease (ERD)

    NCT03943992 · start 2019-01-29

    Registered record
    Registry ID
    NCT03943992
    Conditions
    Erosive Esophagitis
    Interventions
    YYD601 40mg; Nexium 40mg; Placebos
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2019-01-29
    Completion
    2020-07-01
    Enrolment
    170

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionErosive Esophagitis
    InterventionYYD601 40mg; Nexium 40mg; Placebos
    PhasePhase 3
    Registry statusCompleted

  • A Study to Compare PK, PD and Safety of CKD-381 in Healthy Subjects

    NCT03211143 · start 2017-06-20

    Registered record
    Registry ID
    NCT03211143
    Conditions
    GERD
    Interventions
    CKD-381; Nexium
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-06-20
    Completion
    2017-08-28
    Enrolment
    41

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGERD
    InterventionCKD-381; Nexium
    PhasePhase 1
    Registry statusCompleted